Junshi Biosciences
Junshi Biosciences, officially known as Junshi Pharmaceutical Co., Ltd., is a leading biopharmaceutical company headquartered in China. Founded in 2012, the company has rapidly established itself in the global biotechnology landscape, focusing on the research, development, and commercialisation of innovative therapies, particularly in oncology and autoimmune diseases. With a strong presence in major operational regions including Asia and North America, Junshi Biosciences is recognised for its cutting-edge monoclonal antibody products. Notably, its flagship product, toripalimab, has garnered significant attention for its unique mechanism of action in cancer treatment. The company has achieved remarkable milestones, including successful partnerships and regulatory approvals, positioning itself as a key player in the biopharmaceutical industry.
DitchCarbon Score
How does Junshi Biosciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Junshi Biosciences's score of 10 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Junshi Biosciences's reported carbon emissions
Junshi Biosciences, headquartered in China (CN), currently does not have publicly available carbon emissions data or specific reduction targets. As a result, there are no reported figures for their Scope 1, 2, or 3 emissions. The absence of emissions data suggests that the company may still be in the early stages of formalising its climate commitments or reporting practices. In the context of the biopharmaceutical industry, companies are increasingly recognising the importance of sustainability and are often encouraged to set ambitious targets for reducing greenhouse gas emissions. While Junshi Biosciences has not disclosed any specific initiatives or commitments, the industry trend indicates a growing focus on environmental responsibility. As the company progresses, it may adopt strategies aligned with global climate goals, potentially including science-based targets and initiatives aimed at reducing their carbon footprint in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Junshi Biosciences is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
